Sales of nutritional ingredients were expected to rise 6% to 8% in the company’s second quarter of 2014 and instead rose only 2% as a result of the problems with Chinese regulations, said CEO Randy Gress in a earnings call with analysts.
“It just wasn't as great as we expected where we expected some double-digit growth to support our overall growth initiatives there, but we did see some growth within the business and that was due to the headwinds that some of our customers had, with the our overcoming some of the regulations in China for their own supply,” Gress said.
Overall, Innophos recorded net sales of $220 million for the second quarter of 2014 with diliuted earnings per share of 93 cents, compared to 52 cents in the year ago period.